Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression
Author
Oncology Times
Published
Tue 22 Aug 2023
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT-POD_EP43_08152023.mp3.mp3
Share to:
